Jul 3 |
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
|
Jun 26 |
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
|
Jun 17 |
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
|
Jun 13 |
Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now
|
Jun 3 |
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
|
May 29 |
Evaxion Biotech GAAP EPS of $0.03 beats by $0.53, revenue of $0.05M
|
May 28 |
Evaxion Announces Business Update and First Quarter 2024 Financial Results
|
May 24 |
Evaxion Biotech Plans to Unveil 'Positive' Data From Phase 2 Study of Advanced Melanoma Combination Treatment
|
May 23 |
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
|
May 10 |
Evaxion receives Nasdaq notification over minimum stockholders’ equity requirement
|